Interleukin-1: an important target for perinatal neuroprotection?
Sharmony B.Kelly1
Elys Green2
Rod W.Hunt3
Claudia A.Nold-Petry4
Alistair J.Gunn5
Marcel F.Nold3
Robert Galinsky1
1.The Ritchie Centre,Hudson Institute of Medical Research,Melbourne,Victoria,Australia;Department of Obstetrics and Gynaecology,Monash University,Victoria,Australia2.Department of Pediatrics,Monash University,Victoria,Australia;Monash Newborn,Monash Children's Hospital,Melbourne,Australia3.The Ritchie Centre,Hudson Institute of Medical Research,Melbourne,Victoria,Australia;Department of Pediatrics,Monash University,Victoria,Australia;Monash Newborn,Monash Children's Hospital,Melbourne,Australia4.The Ritchie Centre,Hudson Institute of Medical Research,Melbourne,Victoria,Australia;Department of Pediatrics,Monash University,Victoria,Australia5.Department of Physiology,The University of Auckland,Auckland,New Zealand
摘要：Perinatal inflammation is a significant risk factor for lifelong neurodevelopmental impairments such as cerebral palsy. Extensive clinical and preclinical evidence links the severity and pattern of perinatal inflammation to impaired maturation of white and grey matters and reduced brain growth. Multiple pathways are involved in the pathogenesis of perinatal inflammation. However, studies of human and experimental perinatal encephalopathy have demonstrated a strong causative link between perinatal encephalopathy and excessive production of the pro-inflammatory effector cytokine interleukin-1. In this review, we summarize clinical and preclinical evidence that underpins interleukin-1 as a critical factor in initiating and perpatuating systemic and central nervous system inflammation and subsequent perinatal brain injury. We also highlight the important role of endogenous interleukin-1 receptor antagonist in mitigating interleukin-1-driven neuroinflammation and tissue damage, and summarize outcomes from clinical and mechanistic animal studies that establish the commercially available interleukin-1 receptor antagonist, anakinra, as a safe and effective therapeutic intervention. We reflect on the evidence supporting clinical translation of interleukin-1 receptor antagonist for infants at the greatest risk of perinatal inflammation and impaired neurodevelopment, and suggest a path to advance interleukin-1 receptor antagonist along the translational path for perinatal neuroprotection.
机标关键词：interleukin-1targetimportantneuroprotectionperinatal
论文发表日期：2023-01-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：4( 47-50 )
英文信息